Copyright © 2006, European Society of Cardiology
Caveolae and caveolin in transmembrane signaling: Implications for human disease
University of Technology, Dresden, Medical Clinic/Cardiology, Fetscherstr. 76, D-01307 Dresden, Germany
* Corresponding author. Tel.: +49 351 450 1701 (office); fax: +49 351 450 1702. Email address: ruth.strasser{at}mailbox.tu-dresden.de
The identification of various signaling molecules found within caveolae and their functional interaction with the integral membrane protein caveolin, a major structural component of caveolae, suggests that these membrane microdomains participate in transmembrane signaling. Several lines of evidence indicate that caveolin may act as a scaffolding protein by direct interaction with and modulation of the activity of multiple signaling molecules. The compartmentation of various signaling molecules in caveolae and their direct and functional interaction with caveolin provides a paradigm by which these membrane microdomains are involved in regulating signal transduction pathways. By dysregulation of these signal transduction pathways caveolins may be involved in the pathogenesis of various diseases. This review focuses on the implications as well as controversies of the contribution of caveolae and caveolins for several human diseases and the potential implications to therapeutic strategies.
KEYWORDS Caveolae; Caveolin; Human disease; Atherosclerosis; Restenosis; Malignancies
1 Current address: Universitäres Herz-und Gefäβzentrum Hamburg, Prof. Mathey, Prof. Schofer and Partner, Othmarscher Kirchenweg 168, 22763 Hamburg, Germany.
Time for primary review 22 days
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
P. A. Singleton, S. Chatchavalvanich, P. Fu, J. Xing, A. A. Birukova, J. A. Fortune, A. M. Klibanov, J. G. N. Garcia, and K. G. Birukov Akt-Mediated Transactivation of the S1P1 Receptor in Caveolin-Enriched Microdomains Regulates Endothelial Barrier Enhancement by Oxidized Phospholipids Circ. Res., April 24, 2009; 104(8): 978 - 986. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Jin, H. P. Kim, M. Chi, E. Ifedigbo, S. W. Ryter, and A. M. K. Choi Deletion of Caveolin-1 Protects against Oxidative Lung Injury via Up-Regulation of Heme Oxygenase-1 Am. J. Respir. Cell Mol. Biol., August 1, 2008; 39(2): 171 - 179. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. F. Santibanez, F. J. Blanco, E. M. Garrido-Martin, F. Sanz-Rodriguez, M. A. del Pozo, and C. Bernabeu Caveolin-1 interacts and cooperates with the transforming growth factor-{beta} type I receptor ALK1 in endothelial caveolae Cardiovasc Res, March 1, 2008; 77(4): 791 - 799. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Salani, L. Briatore, S. Garibaldi, R. Cordera, and D. Maggi Caveolin-1 Down-Regulation Inhibits Insulin-Like Growth Factor-I Receptor Signal Transduction in H9C2 Rat Cardiomyoblasts Endocrinology, February 1, 2008; 149(2): 461 - 465. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. J. Lim, E. J. Smart, M. Toborek, and B. Hennig The role of caveolin-1 in PCB77-induced eNOS phosphorylation in human-derived endothelial cells Am J Physiol Heart Circ Physiol, December 1, 2007; 293(6): H3340 - H3347. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Verma and A. S. Slutsky Idiopathic Pulmonary Fibrosis -- New Insights N. Engl. J. Med., March 29, 2007; 356(13): 1370 - 1372. [Full Text] [PDF] |
||||





